// App-Quantinova.ai

: A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC.

Researchers

Presenter

  • Michael Paul Kolinsky

Principal Investigators

  • Diletta Bianchini

  • Zafeiris Zafeiriou

  • Niven Mehra

  • Joaquin Mateo

  • Ruth Riisnaes

  • Mateus Crespo

  • Ines Figueiredo

  • Penelope Flohr

  • Nina Tunariu

  • Udai Banerji

  • Florence I. Raynaud

  • Karen E Swales

  • Holly Tovey

  • Nuria Porta

  • Rachel Slade

  • Lorna Leonard

  • Emma Hall

  • Johann S. De Bono

Medical Centers

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • Institute for Cancer Research, London, United Kingdom

  • Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom

  • Cancer Biomarkers Laboratory, The Institute of Cancer Research, London, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Drug Development Unit, Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom

  • Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom

  • Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom

  • The Institute of Cancer Research, Sutton, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • AZD-5363

  • taxane

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Dose Escalation

Phase

  • NA

Study Id's

  • NCT02525068

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved